Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”
Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”
